Balanced news tone
News Sentiment
2509 sentiment intelligence
Qyuns Therapeutics Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
62/100 classification confidence.
directly relevant articles
high-authority source matches
-0.7% over one week, -4.5% over four weeks, trend inactive, and near fair-value range.
Price to earnings forward of Qyuns Therapeutics Co., Ltd. Class H – HKEX:2509
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Price to earnings forward of Qyuns Therapeutics Co., Ltd. Class H – HKEX:2509
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 22:01
- Source
- TradingView
China’s Qyuns moves IL-17 biologic toward first approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 11 Mar 2026 07:00
- Source
- BioWorld News
Fangda Partners Assisted Qyuns Therapeutics in Reaching a License and Collaboration Agreement for the Development and Commercialization of Qx027n with Windward Bio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- Law.asia
Qyuns and Roche partner in $1B+ bispecific antibody deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 29 Oct 2025 07:00
- Source
- BioWorld News
Qyuns’ QX-002N hits endpoints in ankylosing spondylitis trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Feb 2025 08:00
- Source
- BioWorld News